Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 23

Trial Status

Completed2
Terminated1
Other1

Role Distribution

Principal Investigator4
PI Rate100%

Activity Timeline

Clinical Trials (4)

NCT04306965Phase 2Completed
Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab
Atopic Dermatitis
PrincipalinvestigatorStart date: 2020-08-01
NCT04299503Phase 2Withdrawn
Topical Crisaborole in Patients with Alopecia Areata
Alopecia Areata
PrincipalinvestigatorStart date: 2020-03-06
NCT03159936Early Phase 1Terminated
Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)
Discoid Lupus ErythematosusSystemic Lupus Erythematosus
PrincipalinvestigatorStart date: 2017-04-03
NCT02809976Phase 2Completed
Topical Ruxolitinib for the Treatment of Vitiligo
Vitiligo
PrincipalinvestigatorStart date: 2016-01-01

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Similar Key Opinion Leaders

Publications (0)

No publications found for this investigator.

Clinical Trials (4)

Showing 4 of 4 trials

NCT04306965Phase 2PrincipalInvestigator

Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab

Atopic Dermatitis
Completed
NCT04299503Phase 2PrincipalInvestigator

Topical Crisaborole in Patients with Alopecia Areata

Alopecia Areata
Withdrawn
NCT03159936Early Phase 1PrincipalInvestigator

Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)

Discoid Lupus ErythematosusSystemic Lupus Erythematosus
Terminated
NCT02809976Phase 2PrincipalInvestigator

Topical Ruxolitinib for the Treatment of Vitiligo

Vitiligo
Completed

All 4 trials loaded